232 related articles for article (PubMed ID: 36154274)
1. Bacterial Membrane Vesicles as a Novel Strategy for Extrusion of Antimicrobial Bismuth Drug in Helicobacter pylori.
Kumar S; Schmitt C; Gorgette O; Marbouty M; Duchateau M; Giai Gianetto Q; Matondo M; Guigner JM; De Reuse H
mBio; 2022 Oct; 13(5):e0163322. PubMed ID: 36154274
[TBL] [Abstract][Full Text] [Related]
2. Nickel, an essential virulence determinant of Helicobacter pylori: Transport and trafficking pathways and their targeting by bismuth.
Kumar S; Vinella D; De Reuse H
Adv Microb Physiol; 2022; 80():1-33. PubMed ID: 35489790
[TBL] [Abstract][Full Text] [Related]
3. Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication.
Yao X; Xiao S; Zhou L
Helicobacter; 2021 Dec; 26(6):e12846. PubMed ID: 34414638
[TBL] [Abstract][Full Text] [Related]
4. Novel and Effective Therapeutic Regimens for
Hu Y; Zhu Y; Lu NH
Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
[No Abstract] [Full Text] [Related]
5. Development of
Suzuki S; Esaki M; Kusano C; Ikehara H; Gotoda T
World J Gastroenterol; 2019 Apr; 25(16):1907-1912. PubMed ID: 31086459
[No Abstract] [Full Text] [Related]
6. The actions of bismuth in the treatment of Helicobacter pylori infections: an update.
Ge R; Chen Z; Zhou Q
Metallomics; 2012 Mar; 4(3):239-43. PubMed ID: 22358069
[TBL] [Abstract][Full Text] [Related]
7. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis.
Ko SW; Kim YJ; Chung WC; Lee SJ
Helicobacter; 2019 Apr; 24(2):e12565. PubMed ID: 30698318
[TBL] [Abstract][Full Text] [Related]
8. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics.
Marcus EA; Sachs G; Scott DR
Aliment Pharmacol Ther; 2015 Oct; 42(7):922-33. PubMed ID: 26238858
[TBL] [Abstract][Full Text] [Related]
9. Bismuth-Induced Inactivation of Ferric Uptake Regulator from Helicobacter pylori.
He X; Liao X; Li H; Xia W; Sun H
Inorg Chem; 2017 Dec; 56(24):15041-15048. PubMed ID: 29200284
[TBL] [Abstract][Full Text] [Related]
10. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
[TBL] [Abstract][Full Text] [Related]
11. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
12. [Helicobacter pylori - 2012].
Buzás GM
Orv Hetil; 2012 Sep; 153(36):1407-18. PubMed ID: 22951408
[TBL] [Abstract][Full Text] [Related]
13. A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics.
Savarino V; Mansi C; Mele MR; Bisso G; Mela GS; Saggioro A; Caroli M; Vigneri S; Termini R; Olivieri A; Tosatto R; Celle G
Aliment Pharmacol Ther; 1997 Aug; 11(4):699-703. PubMed ID: 9305478
[TBL] [Abstract][Full Text] [Related]
14. Role of Bismuth in the Eradication of Helicobacter pylori.
Alkim H; Koksal AR; Boga S; Sen I; Alkim C
Am J Ther; 2017; 24(6):e751-e757. PubMed ID: 26808355
[TBL] [Abstract][Full Text] [Related]
15. Impact of insufficient doses of medications on
Shi X; Wang C; Meng F; Ma S; Xu G; Liu T; Guo X; Li H; Qi X
Postgrad Med; 2022 Sep; 134(7):668-674. PubMed ID: 35860966
[TBL] [Abstract][Full Text] [Related]
16. Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori.
Bardhan KD; Morton D; Perry MJ; Sanders DS; Morris P; Rowland A; Thompson M; Mitchell TR; Roberts PM
Aliment Pharmacol Ther; 2001 Aug; 15(8):1199-204. PubMed ID: 11472323
[TBL] [Abstract][Full Text] [Related]
17. Role of Hpn and NixA of Helicobacter pylori in susceptibility and resistance to bismuth and other metal ions.
Mobley HL; Garner RM; Chippendale GR; Gilbert JV; Kane AV; Plaut AG
Helicobacter; 1999 Sep; 4(3):162-9. PubMed ID: 10469190
[TBL] [Abstract][Full Text] [Related]
18. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
[TBL] [Abstract][Full Text] [Related]
19. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
Fallone CA; Moss SF; Malfertheiner P
Gastroenterology; 2019 Jul; 157(1):44-53. PubMed ID: 30998990
[TBL] [Abstract][Full Text] [Related]
20. Effect of ranitidine bismuth citrate on the phospholipase A2 activity of Naja naja venom and Helicobacter pylori: a biochemical analysis.
Ottlecz A; Romero JJ; Lichtenberger LM
Aliment Pharmacol Ther; 1999 Jul; 13(7):875-81. PubMed ID: 10383521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
